[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334829-105":59,"doc-detail-334829-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","possible-strategies-to-reduce-the-tumorigenic-risk-of-reprogrammed-normal-and-cancer-cells","Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells","","Reprogramming somatic cells into pluripotent stem cells offers major potential for tissue regeneration and redeveloping materials for transplantation. Induced pluripotent stem cells (iPSCs) can be derived from normal, adult stem, or neoplastic cancer cells and express embryonic stem cell markers, enabling differentiation across tissue types in vitro and in vivo. Tumorigenicity, immunogenicity, and cellular heterogeneity may restrict clinical use because cancer formation depends on mutations in stemness genes and on changes in stem cell niche microenvironments at genetic and epigenetic levels. Chemical-based iPSC generation from human fibroblasts provides a safe, practical manufacturing route to modify cell fate for regeneration therapies. This review emphasizes recent advances to lower iPSC or iPSC-derived organoid tumorigenic risk, improve preparation safety, and support therapeutic benefits.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/possible-strategies-to-reduce-the-tumorigenic-risk-of-reprogrammed-normal-and-cancer-cells/334829/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/possible-strategies-to-reduce-the-tumorigenic-risk-of-reprogrammed-normal-and-cancer-cells/334829.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why can reprogrammed pluripotent cells be unsuitable for therapy?","Question",{"text":112,"@type":113},"Tumorigenicity, immunogenicity, and heterogeneity of reprogrammed cell populations can hinder therapeutic use. The risk is influenced by mutations in stemness genes and by changes in stem cell niche microenvironments at genetic and epigenetic levels.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How are induced pluripotent stem cells (iPSCs) generated in general?",{"text":117,"@type":113},"The review describes reprogramming of somatic cells into pluripotent stem cells using factors such as OCT4, SOX2, KLF4, and C-MYC (OSKM), including additional stemness genes like NANOG in certain combinations.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the focus of the review regarding safety?",{"text":121,"@type":113},"It highlights recent progress aimed at decreasing the tumorigenic risk of iPSCs or iPSC-derived organoids. It also covers strategies to increase safety of iPSC cell preparation and improve therapeutic outcomes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334829,1790669299,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","Review  \nPossible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells  \nYing-Chu Lin 1, Cha-Chien Ku 2,3,4, Kenly Wuputra 2,3,4,5, Chung-Jung Liu 3,6, Deng-Chyang Wu 3,6, Maki Satou 7, Yukio Mitsui 7, Shigeo Saito 2,7,8,* and Kazunari K. Yokoyama 1,2,3,4, *  \nCitation: Lin, Y.-C.; Ku, C.-C.; Wuputra, K.; Liu, C.-J.; Wu, D.-C.; Satou, M.; Mitsui, Y.; Saito, S.; Yokoyama, K.K. Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells. Int. J. Mol. Sci. 2024, 25, 5177 . [https://doi.org/10.3390/ijms25105177](https://doi.org/10.3390/ijms25105177)  \nAcademic Editors: Aleksandra Klimczak, Maria Mesuraca and Maria Concetta Faniello  \nReceived: 16 March 2024  \nRevised: 29 April 2024  \nAccepted: 7 May 2024  \nPublished: 9 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Dentistry, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; [chulin@cc.kmu.edu.tw](chulin@cc.kmu.edu.tw)  \n2 Graduate Institute of Medicine, Department of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; [r991046@gap.kmu.edu.tw](r991046@gap.kmu.edu.tw) (C.-C.K.); [kenlywu@hotmail.com](kenlywu@hotmail.com) (K.W.)  \n3 Regenerative Medicine and Cell Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; [pinkporkkimo@yahoo.com.tw](pinkporkkimo@yahoo.com.tw) (C.-J.L.); [dechwu@yahoo.com](dechwu@yahoo.com) (D.-C.W.)  \n4 Cell Therapy and Research Center, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan  \n5 Waseda Research Institute for Science and Engineering, Waseda University, Tokyo 169-8555, Japan  \n6 Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80756, Taiwan  \n7 Research Institute, Horus Co., Ltd., Iruma 358-0032, Saitama, Japan; [satou.maki@horus-jnl.co.jp](satou.maki@horus-jnl.co.jp) (M.S.); [mitsui.yukio@horus-jnl.co.jp](mitsui.yukio@horus-jnl.co.jp) (Y.M.)  \n8 Saito Laboratory of Cell Technology, Yaita 329-1571, Tochigi, Japan  \n* Correspondence: [saict1@maple.ocn.ne.jp](saict1@maple.ocn.ne.jp) (S.S.); [kazu@kmu.edu.tw](kazu@kmu.edu.tw) (K.K.Y.); Tel.: +886-7312-1001 (ext. 2729) (K.K.Y.); Fax: +886-7313-3849 (K.K.Y.)  \nAbstract: The reprogramming of somatic cells to pluripotent stem cells has immense potential for use in regenerating or redeveloping tissues for transplantation, and the future application of this method is one of the most important research topics in regenerative medicine. These cells are generated from normal cells, adult stem cells, or neoplastic cancer cells. They express embryonic stem cell markers, such as OCT4, SOX2, and NANOG, and can differentiate into all tissue types in adults, both in vitro and in vivo. However, tumorigenicity, immunogenicity, and heterogeneity of cell populations may hamper the use of this method in medical therapeutics. The risk of cancer formation is dependent on mutations of these stemness genes during the transformation of pluripotent stem cells to cancer cells and on the alteration of the microenvironments of stem cell niches at genetic and epigenetic levels. Recent reports have shown that the generation of induced pluripotent stem cells (iPSCs) derived from human fibroblasts could be induced using chemicals, which is a safe, easy, and clinicalgrade manufacturing strategy for modifying the cell fate of human cells required for regeneration therapies. This strategy is one of the future routes for the clinical application of reprogramming therapy. Therefore, this review highlights the recent progress in research focused on decreasing the tumorigenic risk of iPSCs or iPSC-derived organoids and increasing the safety ","cbCaiiI96ZviNeCf","https://ap.wps.com/l/cbCaiiI96ZviNeCf","pdf",1104150,22,"English","# Introduction\n## Tumorigenicity risks in clinical iPSC use\n## Integrating vs nonintegrating reprogramming strategies\n## Viral and nonviral vector approaches","[{\"question\":\"Why can reprogrammed pluripotent cells be unsuitable for therapy?\",\"answer\":\"Tumorigenicity, immunogenicity, and heterogeneity of reprogrammed cell populations can hinder therapeutic use. The risk is influenced by mutations in stemness genes and by changes in stem cell niche microenvironments at genetic and epigenetic levels.\"},{\"question\":\"How are induced pluripotent stem cells (iPSCs) generated in general?\",\"answer\":\"The review describes reprogramming of somatic cells into pluripotent stem cells using factors such as OCT4, SOX2, KLF4, and C-MYC (OSKM), including additional stemness genes like NANOG in certain combinations.\"},{\"question\":\"What is the focus of the review regarding safety?\",\"answer\":\"It highlights recent progress aimed at decreasing the tumorigenic risk of iPSCs or iPSC-derived organoids. It also covers strategies to increase safety of iPSC cell preparation and improve therapeutic outcomes.\"}]","Possible Strategies to Reduce the Tumorigenic Risk of Reprogrammed Normal and Cancer Cells | PDF",1790008465,55]